Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell

SOURCE: Regen BioPharma Inc.

Regen Has Raised Almost $700,000 From "Angel" Investors Since December 29, 2014 to Finance Its Ongoing Research

SAN DIEGO, CA--(Marketwired - Mar 10, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today successful closing of a transaction resulting in acquisition of issued US patent #8,263,571, and associated preclinical data package.The intellectual property covers specific therapeutic agents that gene silence CTCFL.CTCFL, otherwise known as Brother of the Regulator of Imprinted Sites (BORIS) is a gene that is critical for cancer stem cells to survive, in part by inducing expression of telomerase, a protein that creates cellular immortality1.

Thomas Ichim, Ph.D., Chief Scientific Officer of Regen is co-inventor of the patent, which was filed in October 2007 by Vendevia Group. Through a private transaction, Dr. Ichim obtained assignment of the patent and preclinical package, which was subsequently assigned by Dr. Ichim to Regen.

"Having co-authored the peer-reviewed publication dating back to 2008 in which potent inhibition of breast cancer was demonstrated by gene silencing of CTCFL2, and having assigned my own gene silencing/immunotherapy patent to Regen3, I am highly enthusiastic that this very promising approach to killing cancer stem cells has now been brought under the Regen umbrella." Stated Dr. Wei-Ping Min, Professor of Immunology at the University of Western Ontario and Member of Regen's Scientific Advisory Board."The use of RNA interference to kill cancer stem cells adds another powerful weapon in Regen's arsenal on the war on cancer."

CTCFL, also termed Brother of the Regulator of Imprinted Sites (BORIS) is a key protein that was originally discovered by Dr. Victor Lobanenkov at the NIH4, which acts as a "master orchestrator" of numerous genes needed for cancer to maintain the properties of cancer5.Dr. Ichim previously co-authored papers with NIH and other academic groups demonstrating that immunotherapy targeting CTCFL results in regression of breast cancer, leukemia, and glioma6,7,8.

"Having worked for several years on developing the CTCFL gene-silencing therapeutic approach, and witnessing first-hand the promise of this technology in terms of specifically targeting tumor stem cells, I am excited that we identified a mechanism of bringing this highly complementary technology into Regen," said Dr. Ichim. "Currently Regen is using gene silencing to block NR2F6 in cancer stem cells.The acquisition of the CTCFL intellectual property allows for performing experiments in parallel, thus significantly reducing developmental costs while doubling the probability of success."

"The possession of an issued US patent in this rapidly evolving space allows for a wide range of possibilities ranging from internal development, to co-development, to outright licensing," said David Koos, Chairman and CEO of Regen."We have initiated discussions with entities in this industry in order to most rapidly optimize value of this asset."

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Go here to see the original:
Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell